MeSH tree: D02.455.426.559.389.703.757
A research team affiliated with UNIST has made a significant discovery explaining why liver cancers associated with obesity and metabolic disorders tend to be more aggressive and less responsive to conventional treatments. ...
Mar 18, 2026
0
6
Liver cancer is the third-leading cause of cancer deaths worldwide, but a new study shows the solution to targeting this difficult-to-treat disease may already exist.
Oct 14, 2025
0
15
Researchers from the School of Biomedical Sciences at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), have made a significant advancement that could reshape the treatment landscape for hepatocellular carcinoma ...
Aug 13, 2025
0
28
A new exploratory analysis of the HIMALAYA phase III trial involving patients with unresectable hepatocellular carcinoma (uHCC, an advanced liver cancer that could not be treated with surgery or other localized treatments) ...
Jul 22, 2025
0
14
A research team from the School of Clinical Medicine of the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has pioneered the use of a 'dual immunotherapy' combination—nivolumab and ipilimumab (NIVO+IPI)—in ...
Jun 16, 2025
0
44
The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC). The approval of Opdivo plus ...
Apr 16, 2025
0
17
Chemotherapeutic agents are often used to treat cancer. They combat tumor growth, but also have a number of undesirable side effects. One of these is severe muscle wasting, known as chemotherapy-induced cachexia. This chronic ...
Jan 23, 2025
0
38
Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib significantly improved progression-free survival (PFS) and ...
Dec 19, 2024
0
20
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two ...
May 3, 2024
0
79
Hepatocellular carcinoma (HCC) is a common human disease and one of the main causes of cancer-related death. The angiogenesis inhibitor Sorafenib (SORA) is commonly used in the treatment of advanced HCC as a first-line drug.
Feb 7, 2024
0
54
